Form 4 ACADIA PHARMACEUTICALS For: Feb 23 Filed by: Schneyer Mark C.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Acadia Pharmaceuticals (ACAD) PT Lowered to $39 at Mizuho, 'Daybue Seasonality Trend May Raise Concerns'
February 28, 2024 6:15 AM ESTMizuho Securities analyst Uy Ear lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $39.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "With investor focus on the Daybue launch, ACAD will likely trade down today. We would buy on weakness. Investors... More
